Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

By completing this form, you agree that you have viewed our Terms & Conditions and Privacy Policy. Please note that the material contained on this Website is provided solely for informational purposes and does not constitute legal advice. The information is not guaranteed to be correct, complete, or current. Prior results also do not guarantee a similar outcome, as each case must be evaluated on its own merits. Please also note that the Information on the Website is not intended to create, and receipt or viewing does not constitute, or offer to create, an attorney-client relationship between you and Garg Law.

INSIGHTS

March 24, 2026

FDA Launches Unified Adverse Event Monitoring System (AEMS), Expanding Safety Surveillance and Regulatory Oversight

On March 11, 2026, the U.S. Food and Drug Administration (FDA) announced the launch of the Adverse Event Monitoring System (AEMS), a centralized, AI-driven platform that modernizes the agency’s post-market safety surveillance framework across all regulated product categories. These include medical products, vaccines, medical devices, tobacco products, food, cosmetics, and veterinary medicines.

AEMS represents a significant shift from the FDA’s legacy, fragmented reporting infrastructure to a single, integrated system. The platform consolidates multiple existing databases and reporting tools into a unified environment intended to improve data quality, enhance regulatory efficiency, and strengthen the agency’s ability to detect and respond to safety concerns.

Key Features and Implications

  • System Consolidation:

AEMS replaces several legacy systems, including the FDA Adverse Event Reporting System (FAERS), Vaccine Adverse Event Reporting System (VAERS), and other center-specific tools. This consolidation is intended to standardize reporting protocols and improve data consistency across product categories.

  • Expanded Scope:
    The system will cover all FDA-regulated products, including drugs, biologics, vaccines, medical devices, tobacco products, food, cosmetics, and veterinary medicines. Full integration is expected by the end of May 2026, enabling comprehensive cross-product surveillance.
  • Real-Time Data Access:

Unlike prior systems that were updated periodically, AEMS provides real-time access to adverse event data, increasing transparency and enabling more timely signal detection and regulatory response.

  • Advanced Technology and Analytics:

AEMS incorporates AI-based tools for redaction, digitization, and case processing, along with enhanced analytics capabilities. These features are intended to streamline workflows, reduce administrative burden, and support more sophisticated trend analysis across product categories.

  • Centralized Intake Functions:

Beyond adverse event reporting, AEMS will serve as a single platform for managing consumer complaints, regulatory misconduct reports, and whistleblower submissions across all FDA centers.

  • Operational Efficiency:
    The FDA projects that AEMS will reduce annual operating costs and generate approximately $120 million in savings over five years, reflecting efficiencies gained through system consolidation and automation.


Key Takeaways for Stakeholders

Companies regulated by the FDA should anticipate changes in reporting processes and system interfaces as AEMS is implemented. The transition to standardized, real-time reporting may require updates to internal compliance systems, training, and data submission protocols. At the same time, enhanced transparency and analytics may increase regulatory scrutiny and accelerate FDA response times.

Stakeholders should monitor further FDA guidance on implementation timelines, technical specifications, and compliance expectations to ensure readiness for full integration into AEMS.

For more information on AEMS, or for other questions on FDA compliance and enforcement, please email info@garg-law.com.

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.